Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:37 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 7,591 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bones Clear all
Completed No phase listed Observational Results available

A Study to Learn About Recifercept in Patients With Achondroplasia

NCT05659719
View directory record Official record
Conditions
Achondroplasia
Interventions
Recifercept
Other
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 10 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 1 Interventional

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

NCT05444530
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
VAC85135, Ipilimumab
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Duarte, California • Tampa, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Nov 1, 2026, 5:37 PM EST
Terminated Phase 1 Interventional Results available

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

NCT01034592
View directory record Official record
Conditions
Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Interventions
Lenalidomide
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Nov 1, 2026, 5:37 PM EST
Completed No phase listed Observational

Fibergraft Interbody Fusion Retrospective

NCT03898232
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Degeneration, Spinal Stenosis
Interventions
Computed Tomography (CT) Scan of the Lumbar Spine
Radiation
Lead sponsor
Bone and Joint Clinic of Baton Rouge
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Therapeutic Touch for Wrist Fractures in Postmenopausal Women

NCT00079521
View directory record Official record
Conditions
Osteoporosis, Fractures
Interventions
Therapeutic Touch
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
40 Years to 85 Years · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Nov 1, 2026, 5:37 PM EST
Active, not recruiting Phase 3 Interventional

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions
Iomab-B, Conventional Care, HCT
Drug · Procedure
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 2 Interventional Results available

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00831844
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions
cixutumumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Months to 30 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
93
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

NCT02696798
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Nov 1, 2026, 5:37 PM EST
Completed No phase listed Observational

Intraoperative Angioembolization in the Management of Pelvic Fracture-Related Hemodynamic Instability

NCT00755365
View directory record Official record
Conditions
Pelvic Fractures and Associated Hemodynamic Instability
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Nov 1, 2026, 5:37 PM EST
Completed No phase listed Observational

Oral Manifestations of Aplastic Anemia

NCT00006300
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

NCT00719836
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelofibrosis
Interventions
SB1518
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 4 Interventional Results available

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

NCT00957671
View directory record Official record
Conditions
Growth Hormone Deficiency, Traumatic Brain Injury
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Nov 1, 2026, 5:37 PM EST
Withdrawn Phase 1 Interventional

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Nov 1, 2026, 5:37 PM EST
Terminated Not applicable Interventional

Evaluation of Cranioplasty Using Native Bone Autograft Versus Synthetic Bone Allograft

NCT04855175
View directory record Official record
Conditions
Surgical Procedure, Unspecified
Interventions
Synthetic Bone Allograft (ClearFit), Autograft
Device · Other
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Nov 1, 2026, 5:37 PM EST
Recruiting No phase listed Observational

Clinical Outcome Measure at Stryker Spine

NCT06226272
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Scoliosis
Interventions
Spinal Fusion, Spinal Deformities Correction
Device
Lead sponsor
VB Spine, LLC
Industry
Eligibility
18 Years and older
Enrollment
5,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
Jacksonville, Florida • Scarborough, Maine • Southfield, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 1, 2026, 5:37 PM EST
Completed Not applicable Interventional Results available

Improving Cancer Pain Management Through Self-Care

NCT00708019
View directory record Official record
Conditions
Cancer, Pain
Interventions
PRO-SELF PLUS Pain Management Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 2 Interventional Results available

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

NCT00539695
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorder, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-malignant Diseases Requiring Allogeneic HSCT
Interventions
IL-2
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Nov 1, 2026, 5:37 PM EST
Terminated Phase 2 Interventional Results available

Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT01062230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib (Velcade)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Nov 1, 2026, 5:37 PM EST
Recruiting Phase 3 Interventional

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

NCT06934967
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Atlanta, Georgia • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 2 Interventional Results available

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

NCT00141765
View directory record Official record
Conditions
Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer, Brain Tumor, Recurrent
Interventions
Myeloablative Chemotherapy, Stem Cell Rescue
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Nov 1, 2026, 5:37 PM EST
Completed No phase listed Observational

Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive Therapy

NCT04436367
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Nov 1, 2026, 5:37 PM EST
Active, not recruiting Phase 2 Interventional

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT03344211
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Radium Ra 223 Dichloride
Drug · Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 1, 2026, 5:37 PM EST
Terminated Phase 2 Interventional Results available

Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation

NCT01749293
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Haploidentical Transplant, Fludarabine, Busulfan, Total Body Irradiation, Cyclophosphamide
Procedure · Drug · Radiation
Lead sponsor
University of Illinois Chicago
Other
Eligibility
10 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Nov 1, 2026, 5:37 PM EST